Quest Diagnostics Enhances Cancer Monitoring with Haystack ctDNA MRD Testing Innovations
- Quest Diagnostics will present the Haystack MRD® test for cancer monitoring at the 2026 ASCO Gastrointestinal Cancers Symposium.
- Two studies at the symposium will validate the effectiveness of the Haystack MRD test in assessing cancer recurrence.
- Quest Diagnostics emphasizes innovation in diagnostics, enhancing cancer detection and patient outcomes through advanced testing methods.
Quest Diagnostics Advances Cancer Monitoring with Innovative ctDNA Testing
Quest Diagnostics, a key player in diagnostic information services, is poised to make significant contributions to cancer management with its upcoming presentations on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing at the 2026 ASCO Gastrointestinal Cancers Symposium, scheduled for January 8-10 in San Francisco. The focus of these presentations revolves around the Haystack MRD® test, developed by Haystack Oncology, a subsidiary of Quest Diagnostics. This testing method is gaining considerable traction in the oncology field as a means to detect residual or recurring cancer through the analysis of trace amounts of tumor-derived DNA found in the bloodstream.
At the symposium, Quest will highlight two pivotal studies related to the Haystack MRD test. The first study examines the reproducibility and clinical concordance of a tumor-informed MRD assay specifically in patients who have undergone resection for colorectal cancer. The second study investigates the role of ctDNA in monitoring patients receiving total neoadjuvant treatment for locally advanced rectal adenocarcinoma. These studies aim to validate the effectiveness of the Haystack MRD test in enhancing outcomes by providing more accurate assessments of cancer recurrence, thus allowing for timely intervention.
The importance of MRD testing is underscored by a recent Harris Poll survey, which reveals that 96% of oncologists believe that MRD testing can identify cancer recurrence earlier than traditional methods. This insight emphasizes the transformative potential of ctDNA MRD testing in clinical practice. By enabling earlier detection, clinicians can adapt surveillance strategies and treatment plans proactively, potentially intervening before the disease progresses into more advanced stages. With over two decades of development in collaboration with experts from Johns Hopkins School of Medicine, the Haystack MRD test exemplifies a significant advancement in cancer diagnostics, having achieved validation for commercial use in a CLIA-certified laboratory and being accessible for international clinical trials.
In addition to its focus on ctDNA MRD testing, Quest Diagnostics continues to emphasize the importance of innovation in diagnostic services. The company's commitment to advancing cancer detection technologies is evident in its collaborations and research initiatives, which aim to improve patient outcomes through timely and precise diagnostics. As the field of oncology evolves, the integration of advanced testing methods like the Haystack MRD test will be crucial in shaping the future of cancer management and treatment strategies.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

